A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients

Update Il y a 4 ans
Reference: NCT01588769

Woman and Man

  • | Country :
  • Denmark
  • | organs :
  • -
  • | Specialty :
  • -

Extract

It is the primary objective of this study to show safety and tolerability for administration of the cell based immunotherapy ALECSAT to patients with Glioblastoma brain cancer. It is a secondary objective to establish if any indications of positive therapeutic or palliative effects may be observed.


Inclusion criteria

  • Glioblastoma Multiforme

Links